Pfizer inc (PFE)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jul'18Apr'18Dec'17Sep'17Jul'17Apr'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10Dec'09Sep'09Jun'09Mar'09Sep'08Jun'08
Revenues

12,028

12,688

12,680

13,264

13,118

13,977

13,298

13,466

12,906

13,703

13,168

12,896

12,779

13,627

13,045

13,147

13,005

14,047

12,087

11,853

10,864

13,118

12,361

12,773

11,353

13,558

12,643

12,973

12,410

12,851

12,953

13,968

14,885

11,439

16,609

16,485

16,502

15,462

15,995

17,132

16,576

15,797

11,621

10,984

10,867

11,973

12,129

Costs and expenses:
Cost of sales

2,378

2,608

2,602

2,576

2,433

3,075

2,694

2,916

2,563

3,256

2,844

2,660

2,468

3,212

3,085

3,174

2,851

3,411

2,219

2,180

1,838

2,702

2,368

2,462

2,045

2,794

2,287

2,242

2,263

2,391

2,309

2,376

2,745

1,827

3,409

3,571

3,693

3,112

3,790

3,684

4,202

3,506

1,789

1,756

1,408

2,122

2,289

Selling, informational and administrative expenses

2,873

4,240

3,260

3,511

3,339

4,007

3,494

3,542

3,412

4,555

3,504

3,430

3,315

4,429

3,559

3,471

3,385

5,049

3,270

3,386

3,104

3,981

3,556

3,520

3,040

4,152

3,395

3,591

3,217

4,047

3,491

3,665

3,968

3,821

4,457

4,800

4,503

5,197

4,599

4,774

4,403

5,244

3,282

3,350

2,876

3,523

3,863

Research and development expenses

1,724

2,822

2,283

1,842

1,703

2,458

2,008

1,797

1,743

2,315

1,865

1,787

1,716

2,532

1,881

1,748

1,731

2,349

1,722

1,734

1,885

3,209

1,802

1,759

1,623

1,811

1,627

1,530

1,710

1,933

1,887

1,600

2,062

2,183

2,176

2,231

2,091

2,893

2,188

2,181

2,221

2,792

1,632

1,695

1,705

1,885

1,966

Amortization of intangible assets

885

1,031

1,212

1,184

1,183

1,253

1,253

1,191

1,196

1,187

1,177

1,208

1,186

1,121

968

961

1,006

979

937

872

940

949

972

1,001

1,117

1,123

1,117

1,140

1,219

1,203

1,211

1,275

1,420

1,316

1,389

1,384

1,376

1,392

1,156

1,407

1,409

1,122

594

583

578

621

663

Acquisition-related in-process research and development charges

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

74

-

-

20

-

13

156

Restructuring charges and certain acquisition-related costs

69

451

365

-115

46

872

85

44

43

83

114

70

84

577

531

316

141

425

581

86

60

130

-19

81

58

635

233

183

131

717

312

184

597

379

1,090

478

894

1,055

499

885

706

3,124

193

459

554

366

569

(Gain) on completion of Consumer Healthcare JV transaction

6

-

8,087

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other Nonoperating Income (Expense)

-221

-3,041

-319

-126

-92

-3,259

414

551

178

-1,352

-79

75

-60

-979

-1,417

-1,068

-330

-2,190

-661

-55

46

-345

-94

53

-623

18

-411

1,070

-145

-739

-937

-688

-1,658

-689

-547

-423

-827

-905

-2,349

-275

-412

-460

160

72

-57

721

-167

Income from continuing operations before provision for taxes on income

3,885

-1,509

10,727

4,141

4,323

-946

4,177

4,527

4,127

954

3,585

3,815

3,951

776

1,604

2,410

3,561

-353

2,697

3,539

3,082

1,803

3,587

4,003

2,847

3,061

3,573

5,357

3,725

1,821

2,806

4,180

2,435

1,224

3,541

3,598

3,118

982

1,414

3,926

3,149

-149

3,971

3,049

3,803

2,722

2,790

Provision for taxes on income

475

-1,181

3,047

-915

433

-564

66

648

556

-11,336

727

739

821

14

249

347

513

-188

567

905

706

545

911

1,082

582

430

985

1,782

1,109

513

-183

1,180

711

434

1,216

1,077

894

-2,012

558

1,472

1,135

-807

1,092

786

1,074

463

25

Income from continuing operations

3,410

-327

7,680

5,056

3,889

-382

4,111

3,879

3,571

12,288

2,858

3,077

3,130

764

1,355

2,062

3,048

-166

2,130

2,635

2,376

1,257

2,676

2,921

2,265

2,631

2,588

3,575

2,616

1,308

2,989

3,000

1,724

790

2,325

2,521

2,224

2,994

856

2,454

2,014

658

2,879

2,263

2,729

2,259

2,765

Discontinued operations:
Income from discontinued operations––net of tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

36

141

-

-

225

260

-

-

96

-

-

-95

26

31

19

-

-

-

-

-

-

Gain on disposal of discontinued operations––net of tax

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-25

10,418

-

-

0

0

-

-

1,328

-

-

-2

-11

0

2

-

-

-

-

-

-

Discontinued operations––net of tax

0

0

4

0

0

0

11

0

-1

0

0

2

0

16

0

1

0

-3

8

1

5

-22

-3

0

73

-57

11

10,559

149

5,013

225

260

79

658

1,424

97

10

-97

15

31

21

108

2

3

1

25

17

Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

3,410

-327

7,684

5,056

3,889

-383

4,122

3,879

3,570

12,289

2,858

3,078

3,130

780

1,355

2,063

3,048

-169

2,139

2,635

2,381

1,237

2,672

2,921

2,338

2,574

2,599

14,134

2,765

6,321

3,214

3,260

1,803

1,448

3,749

2,618

2,234

2,897

871

2,485

2,035

766

2,881

2,266

2,730

2,284

2,782

Less: Net income attributable to noncontrolling interests

9

9

4

10

6

12

8

7

9

15

18

5

9

6

0

16

9

2

9

9

6

8

6

9

9

6

9

39

15

6

6

7

9

9

11

8

12

7

5

10

9

-1

3

5

1

6

6

Net income attributable to Pfizer Inc.

3,401

-337

7,680

5,046

3,884

-394

4,114

3,872

3,561

12,274

2,840

3,073

3,121

775

1,355

2,047

3,038

-172

2,130

2,626

2,376

1,228

2,666

2,912

2,329

2,568

2,590

14,095

2,750

6,315

3,208

3,253

1,794

1,439

3,738

2,610

2,222

2,890

866

2,475

2,026

767

2,878

2,261

2,729

2,278

2,776

Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)

0.61

-0.06

1.38

0.91

0.69

-0.06

0.70

0.66

0.60

2.05

0.48

0.52

0.52

0.13

0.22

0.34

0.49

-0.02

0.34

0.43

0.38

0.20

0.42

0.46

0.35

0.41

0.39

0.51

0.36

0.18

0.40

0.40

0.23

0.10

0.30

0.32

0.28

0.37

0.11

0.30

0.25

0.04

0.43

0.34

0.41

0.34

0.41

Discontinued operations––net of tax (in dollars per share)

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.01

0.04

0.00

1.50

0.02

0.68

0.03

0.03

0.01

0.09

0.18

0.01

0.00

-0.01

0.00

0.01

0.00

0.02

0.00

0.00

0.00

0.00

0.00

Net income attributable to Pfizer Inc. common shareholders (in dollars per share)

0.61

-0.06

1.38

0.91

0.69

-0.06

0.70

0.66

0.60

2.05

0.48

0.52

0.52

0.13

0.22

0.34

0.49

-0.03

0.35

0.43

0.38

0.20

0.42

0.46

0.36

0.46

0.39

2.00

0.38

0.85

0.43

0.44

0.24

0.19

0.48

0.33

0.28

0.36

0.11

0.31

0.25

0.05

0.43

0.34

0.41

0.34

0.41

Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)

0.61

-0.06

1.36

0.89

0.68

-0.07

0.69

0.65

0.59

2.03

0.47

0.51

0.51

0.13

0.22

0.33

0.49

-0.03

0.34

0.42

0.38

0.19

0.42

0.45

0.35

0.40

0.39

0.50

0.36

0.17

0.40

0.40

0.23

0.09

0.30

0.32

0.28

0.37

0.11

0.30

0.25

0.04

0.43

0.34

0.40

0.33

0.41

Discontinued operations––net of tax (in dollars per share)

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.01

0.04

0.00

1.48

0.02

0.67

0.03

0.03

0.01

0.09

0.18

0.01

0.00

-0.01

0.00

0.01

0.00

0.02

0.00

0.00

0.00

0.01

0.00

Net income attributable to Pfizer Inc. common shareholders (in dollars per share)

0.61

-0.06

1.36

0.89

0.68

-0.06

0.69

0.65

0.59

2.03

0.47

0.51

0.51

0.13

0.22

0.33

0.49

-0.03

0.34

0.42

0.38

0.19

0.42

0.45

0.36

0.44

0.39

1.98

0.38

0.84

0.43

0.43

0.24

0.18

0.48

0.33

0.28

0.35

0.11

0.31

0.25

0.06

0.43

0.34

0.40

0.34

0.41

Weighted-average shares––basic

5,545

5,534

5,545

5,562

5,635

5,790

5,875

5,866

5,957

5,965

5,951

5,958

6,006

6,072

6,066

6,068

6,150

6,174

6,168

6,159

6,203

6,297

6,330

6,368

6,389

6,442

6,581

7,042

7,187

7,319

7,436

7,476

7,537

7,641

7,770

7,875

7,982

8,010

8,027

8,046

8,061

7,847

6,730

6,728

6,723

6,718

6,732

Weighted-average shares––diluted

5,613

5,629

5,649

5,672

5,750

5,913

5,986

5,952

6,057

6,062

6,041

6,037

6,092

6,112

6,150

6,149

6,225

6,250

6,243

6,243

6,292

6,373

6,403

6,444

6,476

6,538

6,656

7,117

7,269

7,389

7,508

7,537

7,598

7,700

7,810

7,935

8,035

8,066

8,057

8,072

8,101

7,913

6,762

6,752

6,753

6,736

6,748

Cash dividends paid per common share (in dollars per share)

-

-

-

-

-

-

-

-

-

-

0.32

0.32

0.32

-

0.30

0.30

0.30

0.28

0.28

0.28

0.28

0.26

0.26

0.26

0.26

0.24

0.24

0.24

0.24

0.22

0.22

0.22

0.22

0.20

0.20

0.20

0.20

0.18

0.18

0.18

0.18

-

0.16

0.16

0.32

0.32

0.32